Mucoviscidosis
Conditions
Interventions
Active substance: LUM/IVA fixed-dose combination
Activity: CFTR corrector and potentiator (chloride ion secretion)
Strength and route of administration: 200-mg lumacaftor/125-mg ivacaftor
(200/125 mg)
Cystic
Fibrosis
Mutation
Sponsors
Vertex Pharmaceuticals
Eligibility
Age
12 Years to 64 Years
Inclusion criteria
Inclusion criteria: Subjects who meet all of the following inclusion criteria will be eligible: 1. Male or female with confirmed diagnosis of CF. The subject must have both of the following: o One or more characteristic phenotypic features, such as chronic cough and sputum production, persistent chest radiograph abnormalities, or airway obstruction manifested by wheezing and air trapping; or a history of CF in a sibling; or a positive newborn screening test result; o An increased sweat chloride concentration by pilocarpine iontophoresis on two or more occasions; or identification of two CF mutations; or demonstration of abnormal nasal epithelial ion transport. 2. Age 12 years or older on the date of informed consent. 3. All subjects must have an A455E mutation on at least 1 CFTR allele. 4. Forced expiratory volume in one second (FEV1) *30% of predicted and *90% of predicted at the Screening Visit, based on the Global Lung Function Initiative (GLI)- 2012 multi-ethnic all-age reference equations. 5. Stable CF disease as judged by the investigator. 6. Willing to remain on a stable medication regimen for CF from 4 weeks before Day 1 through the Follow-up Visit. 7. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. 8. Subject (or subject*s legally appointed and authorized representative) will sign and date an informed consent form (ICF), and where appropriate, assent form.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following exclusion criteria will not be eligible: 1. History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. For example: o A history of cirrhosis with portal hypertension. o An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (the first dose of study drug). 2. A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H mutation on at least one CFTR allele. 3. Ongoing or prior participation in an investigational drug study (including studies investigating LUM/IVA or IVA) within 30 days before the Screening Visit. o A washout period of 5 terminal half-lives of the previous investigational study drug or 30 days, whichever is longer, must elapse before the Screening Visit. The duration of the elapsed time may be longer if required by local regulations. o Subjects who participated in Vertex Study VX14-661-108 may not be enrolled. o Ongoing participation in a noninterventional study (including observational studies) is permitted. 4. Pregnant or breastfeeding. 5. Any of the following abnormal laboratory values at the Screening Visit: * Hemoglobin 5 × ULN * Bilirubin >2 × ULN * Glomerular filtration rate *45 mL/min/1.73 m2 (calculated by the Counahan-Barratt equation).25 6. History of cataract/lens opacity, or evidence of cataract/lens opacity determined to be clinically significant by the ophthalmologist or optometrist during the ophthalmologic examination at the Screening Visit (if applicable). 7. Use of strong inhibitors or strong inducers of CYP3A, including consumption of certain herbal medications (e.g., St. John*s Wort) and certain fruit and fruit juices, within 14 days before Day 1 (the first dose of study drug). 8. Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements outlined in Section 11.6.5.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) through 8 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Change from baseline in sweat chloride through 8 weeks of treatment. * Change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at 8 weeks of treatment. * Organoid-based measurements of LUM/IVA-induced CFTR function in vitro versus clinical outcomes. * Change from baseline in glucose and insulin levels during the oral glucose tolerance test (OGTT) after approximately 8 weeks of treatment. | — |
Countries
The Netherlands
Outcome results
None listed